Table 1.
Characteristics of 37 breast cancer patients by human epidermal growth factor receptor 2 (HER2) status [N (%) or M ± SD]
| All | HER2 status | p value | ||
|---|---|---|---|---|
| Negative | Positive | |||
| N | 37 | 25 | 12 | |
| Mean age ± SD | 50.6 ± 12.3 | 51.7 ± 13.7 | 48.3 ± 8.93 | 0.43a |
| Menopausal status | ||||
| Premenopause | 20 (54) | 12 (48) | 8 (67) | |
| Postmenopause | 17 (46) | 13 (52) | 4 (33) | 0.32b |
| Race/ethnicity | ||||
| Hispanic | 27 (73) | 18 (72) | 9 (75) | |
| Non-Hispanic | 10 (27) | 7 (28) | 3 (25) | 1.00b |
| Body mass index (BMI), kg/m2 | ||||
| Mean BMI ± SD | 30.6 ± 7.9 | 31.2 ± 8.3 | 29.5 ± 7.1 | 0.67a |
| < 25 | 9 (24) | 7 (28) | 2 (17) | |
| 25–30 | 14 (38) | 8 (32) | 6 (50) | |
| > 30 | 14 (38) | 10(40) | 4 (33) | 0.67 b |
| Total body fat (TBF) | ||||
| Mean % fat ± SD | 42.7 ± 6.9 | 42.6 ± 7.5 | 42.9 ± 5.8 | 0.90a |
| ≤ 46% | 25 (68) | 19 (76) | 6 (50) | |
| > 46% | 12 (32) | 6 (24) | 6 (50) | 0.15b |
| BMI and TBF | ||||
| I (< 25 & ≤ 46%) | 9 (24) | 7 (28) | 2 (17) | |
| II (≥ 25 & ≤ 46%) | 16 (43) | 12 (48) | 4 (33) | |
| III (≥ 25 & > 46%) | 12 (32) | 6 (24) | 6 (50) | 0.36b |
| Age at menarche | ||||
| Mean age ± SD | 12.4 ± 1.5 | 12.2 ± 1.5 | 12.7 ± 1.5 | 0.49a |
| ≤ 11 | 11 (30) | 7 (28) | 4 (33) | |
| 12 | 9 (24) | 7 (28) | 2 (17) | |
| ≥ 13 | 17 (46) | 11(44) | 6 (50) | 0.81 b |
| Parity | ||||
| Mean parity ± SD | 1.8 ± 1.3 | 1.8 ± 1.2 | 1.9 ± 1.6 | 0.73a |
| No | 8 (22) | 6 (24) | 2 (17) | |
| 1–2 | 18 (49) | 13 (52) | 5 (42) | |
| ≥ 3 | 11 (30) | 6 (24) | 5 (42) | 0.65 b |
| Stage at diagnosis | ||||
| I/II | 22 (59) | 15 (60) | 7 (58) | |
| III | 15 (41) | 10 (40) | 5 (42) | 1.00b |
| Grade of tumor | ||||
| I/II | 14 (38) | 12 (48) | 2 (17) | 0.08b |
| III | 23 (62) | 13 (52) | 10(83) | |
| ER/PR status | ||||
| ER+PR+ | 23 (62) | 19 (76) | 4 (33) | |
| ER+PR− | 5 (14) | 0 (0) | 5 (42) | |
| ER−PR− | 9 (24) | 6 (24) | 3 (25) | 0.001b |
aWilcoxon rank sum test between HER2+ vs HER2− group for age, BMI, parity, and age at menarche
bFisher exact test between HER2+ vs HER2− group for all other variables